- Lantern owns an AI drug development platform called RADR that increases in value each day as it analyzes more data points.
- Using this platform, Lantern has generated an impressive internal pipeline of several different drugs including LP-100, LP-300, LP-184, and LP-284.
- In late 2021 and 2022 the company plans to progress several of these drugs into clinical trials and continue to discover new molecules.
- Recently, the company signed its first partnership with Actuate Therapeutics to license its platform for equity, moving it one step closer to billion-dollar competitor Schrodinger.
- The company has 4 years of cash runway, removing the risk of a capital raise for a long time.
For further details see:
Lantern Pharma: Drug Recycling With AI